BMI Association With Treatment Outcomes in Head and Neck Cancer Patients Receiving Immunotherapy: A Comprehensive Review and Meta‐Analysis

作者：Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, Diego Olavarria Bernal, Hector Garcia Pleitez, Lukman Tijani · 发表于：Cancer Reports · 年份：2025 · DOI：10.1002/cnr2.70147 · 被引用次数：7 · 研究领域：Cancer Risks and Factors、Nutrition and Health in Aging、Head and Neck Cancer Studies

BACKGROUND: In recent years, immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies. As such, numerous ICIs are establishing themselves as prospective therapy alternatives for individuals with head and neck cancer (HNC). Evidence suggests a potential correlation between body mass index (BMI) and the efficacy of ICIs in cancer patients. However, this association in HNC patients subjected to immunotherapy is still unclear. AIMS: To investigate the effect of BMI on the survival outcomes of HNC patients treated with immunotherapy. METHODS: PubMed, Web of Science, and Google Scholar databases were searched extensively for records published until January 2024. Full-text articles aligned with the research objective were included, while records published in English, case reports, reviews, editorials, and studies reporting immunotherapy combined with other cancer therapies were excluded. The data required for review and analysis was abstracted in Excel files by two independent reviewers. Additionally, data synthesis was carried out using the Review Manager program, and evaluation of methodological quality was done with the Newcastle Ottawa scale. The statistical analyses were stratified according to the BMI values, of which patients were categorized as follows: Obese (BMI ≥ 27.5), non-obese (BMI < 27.5), overweight (BMI: 23.5-27.5), underweight (BMI < 18.5), normal (BMI: 18.5-23.5), low (BMI < 20), and high (BMI ≥ 20). RESULTS...